SURI

Simplify Propel Opportunities ETF

Spotlight Banner
as of 03/17/2023

NAV

$ 21.33

NAV Change

- $ 0.21 /0.97%

Price

$ 21.21

Price Change

- $ 0.30 /1.39%
The Simplify Propel Opportunities ETF (SURI) seeks to provide long-term growth of capital by providing investors with exposure to biotech, pharma, health care technology, and life science companies that are believed to be overlooked by investors, thereby presenting significant opportunities for capital appreciation.

The fund is sub-advised by Propel, which uses its deep scientific and commercial expertise in health sciences to identify the most promising health science investment opportunities.

Fund Overview

As of 03/17/2023

Ticker Symbol
SURI
Gross Expense Ratio
2.76%
Net Expense Ratio
2.51%
CUSIP
82889N624
Total Assets
$62,498,318.74
Shares Outstanding
2,930,001
SEC 30-Day Yield as of 02/28/2023 SEC 30-day Yield is available once fund has a full quarter of performance.
SEC 30-Day Yield Close
SEC 30-day Yield is available once fund has a full quarter of performance.
-
Unsubsidized 30-Day SEC Yield as of 02/28/2023
-
Distribution Frequency
N/A
Distribution Yield as of 03/17/2023 Distribution yield calculation employs the most recent distribution, and multiplies the payment by 12 (monthly) or 4 (quarterly) to get an annualized total. The annualized total is then divided by the most recent net asset value (NAV) to determine the distribution yield.
Distribution Yield Close
Distribution yield calculation employs the most recent distribution, and multiplies the payment by 12 (monthly) or 4 (quarterly) to get an annualized total. The annualized total is then divided by the most recent net asset value (NAV) to determine the distribution yield.
-
Options Available
No
Inception Date
02/07/2023
Premium/Discount (%) as of 03/17/2023
-0.56%
NAV
$21.33
NAV Per Share as of 03/17/2023
$21.33
Market Price as of 03/17/2023
$21.21
30-Day Median Bid-Ask Spread
0.77%
Bid/Ask
$21.16/$21.44
Midpoint Price
$21.30
Volume
100,390
NAV Symbol
SURI.NV
IOPV Symbol
SURI.IV
Shares Out. Symbol
SURI.SO

Management Fees

This table describes the fees and expenses that you may pay if you buy, sell, and hold shares of the Fund. Investors purchasing or selling shares of the Fund in the secondary market may be subject to costs (including customary brokerage commissions) charged by their broker. The fee table located in the prospectus and updates in prospectus supplements prevail.

Annual Fund Operating Expenses (expenses that you pay each year as a percentage of the value of your investment)
Management Fees1 2.75%
Distribution and Service (12b-1) Fees 0.00%
Other Expenses2 0.00%
Acquired Fund Fees and Expenses3 0.01%
Total Annual Fund Operating Expenses 2.76%
Fee Waiver4 (0.25)%
Total Annual Fund Operating Expenses After Fee Waiver 2.51%
1. Estimated for the Fund’s initial fiscal year. The Fund has agreed to pay the adviser as compensation under a management agreement a monthly advisory fee (as a percentage of daily net assets) computed at the annual rate of 2.75% on assets up to $1 billion; 2.50% on assets over $1 billion and less than $5 billion; 2.00% on assets over $5 billion and less than $10 billion; and 1.00% on assets over $10 billion.

2. Other Expenses are estimated for the Fund’s initial fiscal year.

3. Acquired Fund Fees and Expenses, are estimated for the Fund’s initial fiscal year, are the indirect costs of investing in other investment companies. The operating expenses in this fee table will not correlate to the expense ratio in the Fund’s financial highlights located in the prospectus because the financial statements include only the direct operating expenses incurred by the Fund.

4. The adviser and sub-adviser have collectively agreed to waive 0.25% of the management and subadvisory fee on an annualized basis through December 31, 2023. This waiver may be terminated by the Fund's Board of Trustees on 60 days' notice and terminates automatically if the management agreement or sub-advisory agreement is terminated.

Fund Performance

As of 02/28/2023 12/31/2022

Cumulative 1 Month 3 Month 6 Month YTD 1 Year Since Inception
NAV -4.48%
Market Price -3.16%
Annualized 1 Year 3 Year Since Inception
NAV
Market Price
Cumulative 1 Year Since Inception
NAV
Market Price
Annualized 1 Year 3 Year 5 Year Since Inception
NAV
Market Price

Historical Premium/Discount

Ticker Name Quantity Weight
PAGP Plains GP Holdings LP 1059027 20.77%
SLQD iShares 0-5 Year Investment Grade Corporate Bond ETF 84000 6.46%
ATHA ATHIRA PHARMA INC USD 0.0001 1390148 5.74%
MDGL Madrigal Pharmaceuticals Inc 14294 5.73%
MCRB SERES THERAPEUTICS INC USD 0.001 550626 4.94%
SPSB SPDR SERIE LEHMAN SHRT TRM CORPOR E 101550 4.79%
REPL Replimune Group Inc 150000 4.70%
ANNX ANNEXON INC 653483 4.26%
RNA AVIDITY BIOSCIENCES INC 125000 4.10%
APLT APPLIED THERAPEUTICS INC 2382621 3.63%
SAGE SAGE THERAPEUTICS INC USD 0.0001 50030 3.42%
FLRN SPDR Bloomberg Barclays Investment Grade Floating Rate ETF 61480 2.98%
KYN KAYNE ANDE COM STK USD0.001 212238 2.74%
MIRM Mirum Pharmaceuticals Inc 70000 2.58%
FULC Fulcrum Therapeutics Inc 465000 2.57%
AKRO Akero Therapeutics Inc 39777 2.56%
PHAT Phathom Pharmaceuticals Inc 237935 2.51%
TCRX TCRX 546916 2.36%
ALLO Allogene Therapeutics Inc 245000 2.15%
EIGR EIGER BIOPHARMACEUTICALS INC 1099653 1.94%
STOK Stoke Therapeutics Inc 122796 1.75%
KURA Kura Oncology Inc 80000 1.50%
MRNS MARINUS PHARMACEUTICALS INC NPV 131759 1.43%
HRTX HERON THERAPEUTICS INC USD 0.01 306590 1.14%
STRO Sutro Biopharma Inc 120000 1.00%
KDNY Chinook Therapeutics Inc 25000 0.89%
FLOT ISHARES TR FLOATING RATE BD ETF 10500 0.84%
XFOR XFOR 400000 0.54%
KYMR KYMERA THERAPEUTICS INC 10532 0.52%
OMGA OMEGA THERAPEUTICS INC 27859 0.44%
ACET Adicet Bio Inc 26900 0.32%
CYBN CYBIN INC 500000 0.31%
ATAI ATAI LIFE SCIENCES NV 140000 0.27%
ADAP ADAPTIMMUNE THERAPEUTICS-ADR 150000 0.27%
AGIO AGIOS PHARMACEUTICALS INC USD 0.001 5792 0.22%
PAA Plains All American Pipeline L
JPST JPMORGAN ULTRA-SHORT INCOME
ICSH ICSH
- Estimated Cash -1493352 -2.39%